Compare Abeona Therapeutics Inc (ABEO) vs GoPro Inc (GPRO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs GoPro Inc — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while GoPro Inc trades at $0.72 (market cap $121.79M). The key difference: Abeona Therapeutics Inc is far larger — about 3.1× GoPro Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | GPRO | |
|---|---|---|
Market Cap | $373.32M | $121.79M |
Sector | Health | Technology |
52-Week High | $7.23 | $2.88 |
52-Week Low | $4.17 | $0.64 |
Enterprise Value | $228.22M | $169.74M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
GoPro (GPRO) trades at $0.701, down 3.96% for the day, reflecting persistent financial distress. The stock shows a bearish technical outlook with negative cash flows and consecutive earnings misses. Recent news highlights a strategic review for potential sale or merger, announced on May 11, 2026, following weak Q1 2026 results. Revenue has declined from $1.1B in 2022 to $652M in 2025, with net losses deepening, indicating significant operational challenges.
The investment outlook remains highly speculative. The strategic sale process offers a potential catalyst, but substantial risks include ongoing cash burn, negative equity, and competitive pressures. Analyst sentiment is mixed with a cautious hold bias. Investors should weigh the binary outcome of a successful strategic transaction against the company's fundamental deterioration and explicit going-concern risks noted in recent disclosures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →
